AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) for violations of §§10(b) and 20(a)...
Covered in this story
What has happened since
- Aardvark Therapeutics Inc is down 12.4% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AARD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aardvark Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.